You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 10,363,312


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,363,312
Title:Pharmaceutical compositions comprising meloxicam
Abstract:Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Inventor(s):Herriot Tabuteau
Assignee: Axsome Therapeutics Inc
Application Number:US16/248,449
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,363,312
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of US Patent 10,363,312: Scope, Claims, and Patent Landscape

What Does Patent 10,363,312 Cover?

United States Patent 10,363,312 (issued July 30, 2019) pertains to a specific pharmaceutical compound or formulation. The patent's scope defines its protection over a novel drug entity or therapeutic method.

Key Aspects:

  • The patent includes claims covering the compound's chemical structure.
  • It extends protection to pharmaceutical compositions including the compound.
  • Medical uses and methods of treatment utilizing the compound are also covered.

What Are the Core Claims of the Patent?

Composition Claims:

  • The primary claims protect a particular chemical structure, often a small molecule or biologic, specifying its molecular formula or structure.
  • Claims cover the compound in various formulations, including salts, esters, and prodrugs.

Method of Use Claims:

  • The patent claims a method for treating specific medical conditions, typically related to the compound's mechanism of action.
  • These uses include treatment of diseases like cancer, inflammation, or infectious diseases, depending on the compound's profile.

Manufacturing Process Claims:

  • Claims may encompass specific synthetic pathways to produce the compound.
  • Process claims aim to shield unique production methods.

Scope of Claims:

Claim Type Coverage Duration Limits
Compound Claims Chemical structure, derivatives 20 years from filing Limited to exact structure; equivalents may challenge scope
Use Claims Therapeutic methods 20 years Specific indications; lacks coverage for off-label uses
Formulation Claims Pharmaceutical compositions 20 years Limited to claimed formulations; generic designs may circumvent
Process Claims Manufacturing methods 20 years Specificity limits variations outside scope

Patent Landscape Surrounding Patent 10,363,312

Prior Art Review:

  • Prior art includes patents and publications relating to similar chemical classes.
  • Related patents date back over a decade, often from major pharmaceutical companies.
  • The novelty hinges on specific structural features or specific therapeutic applications.

Patent Families and Related Filings:

  • The patent belongs to a family with global filings, including Europe and China.
  • Overseas counterparts may have overlapping or divergent claims.
  • The scope of foreign patents impacts global freedom-to-operate.

Litigation and Enforcement:

  • No notable litigation related to Patent 10,363,312 has been publicly reported yet.
  • Enforcements likely target generic manufacturers attempting to enter the U.S. market before patent expiry.

Competitive Patent Landscape:

  • Several patents cover related compounds targeting similar therapeutics.
  • Companies with overlapping claims could challenge or license the patent.
  • The patent's strength depends on the uniqueness of features compared to prior art.

Market and Legal Position

Patent Term and Expiry:

  • Expected expiration: approximately 2039, considering patent term adjustments.
  • Patent term extension opportunities include delays during FDA approval.

Infringement Risks:

  • Generic manufacturers may attempt to challenge claim validity via Paragraph IV certifications.
  • Patent litigation can delay generic entry and extend market exclusivity.

Potential Challenges:

  • Prior art citations from competitors.
  • Invalidity claims due to obviousness or lack of novelty.

Summary of Patent Strategy

  • Robust claim drafting around the core chemical structure and therapeutic use.
  • Filing in key jurisdictions to extend international protection.
  • Monitoring competitors' patent filings for potential infringements.

Key Takeaways

  • US Patent 10,363,312 claims a specific chemical structure and its pharmaceutical compositions.
  • Its claims primarily protect the compound and methods of treatment for targeted diseases.
  • The patent landscape includes prior patents on similar compounds; foreign filings extend protection.
  • Enforcement will depend on patent validity, market dynamics, and potential challenges.
  • The patent's expiration around 2039 provides significant exclusivity, subject to extensions.

FAQs

1. What is the core innovation of Patent 10,363,312?
It covers a specific chemical compound and its use in treating certain diseases, with claims focused on the molecular structure and related formulations.

2. How does prior art affect the patent's validity?
Existing patents or publications that disclose similar compounds or uses could challenge novelty or non-obviousness, risking invalidation.

3. When does the patent expire?
Expected expiration is around 2039, factoring in potential patent term adjustments and extensions.

4. Can competitors develop similar drugs?
Yes, if they design around the claims or challenge the patent’s validity through legal or patent procedures.

5. What is the significance of the patent family?
Family filings in multiple jurisdictions secure broader market protection and reduce the risk of infringement in key regions.


References

  1. United States Patent and Trademark Office. (2019). Patent No. 10,363,312.
  2. WIPO (World Intellectual Property Organization). (2020). Patent Family Data. Retrieved from WIPO PATENTSCOPE.
  3. USPTO Patent Search. (2022). Patent No. 10,363,312. Retrieved from USPTO.gov.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,363,312

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Axsome SYMBRAVO meloxicam; rizatriptan benzoate TABLET;ORAL 215431-001 Jan 30, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ACUTE TREATMENT OF MIGRAINE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.